850424-11-2

Usage

Uses

Used in Pharmaceutical Development:
2-Chloro-6-methoxy-quinazoline is used as a potential pharmaceutical candidate for drug development in the field of medicinal chemistry. Its unique structural features and potential pharmacological effects make it a promising compound for further research and exploration of its utility in various medicinal applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-Chloro-6-methoxy-quinazoline is used as a subject of study to investigate its properties and potential uses. 2-Chloro-6-methoxy-quinazoline's structural characteristics and biological activities may reveal its applicability in the development of new drugs and therapeutic agents.
Used in Industrial Applications:
While the primary focus of 2-Chloro-6-methoxy-quinazoline is in the pharmaceutical sector, its unique chemical properties may also find utility in various industrial applications. Further research into its properties and potential uses may uncover additional areas where 2-Chloro-6-methoxy-quinazoline can be effectively employed.

Upstream product

• 850424-10-1 6-methoxyquinazolin-2-ol 
• 850424-09-8 ethyl (2-formyl-4-methoxyphenyl)carbamate 
• 850424-08-7 ethyl (2-(1,3-dioxolan-2-yl)-4-methoxyphenyl)carbamate 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 20357-24-8 5-methoxy-2-nitro-benzaldehyde 
• 64389-34-0 5-methoxy-2-aminobenzaldehyde ethylene acetal 
• 73428-02-1 5-methoxy-2-nitrobenzaldehyde ethylene acetal 
• 32618-84-1 6-Methoxyquinazolin-2,4-dione 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 105763-77-7 2,4-dichloro-6-methoxy-quinazoline 

Downstream Products

• 850424-12-3 (4-bromophenyl)(6-methoxyquinazolin-2-yl)amine 
• 1036755-97-1 2-chloroquinazolin-6-ol 
• 1361129-27-2 C₂₅H₂₅N₅O₂ 
• 1361129-30-7 2-(4-isopropylphenylamino)quinazolin-6-ol 
• 850424-16-7 C₁₈H₁₉N₃O 
• 1374336-64-7 N-(4-isopropylphenyl)-6-methoxyquinazolin-2-amine 
• 850424-15-6 C₁₉H₂₁N₃O 
• 1383379-76-7 4-(6-methoxyquinazolin-2-yl)benzoic acid 
• 1383379-46-1 4-(6-hydroxyquinazolin-2-yl)benzoic acid 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF

The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.

BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory dis

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors

Compounds belonging to several scaffolds-quinazolines, quinolines and quinoxalines-were designed and synthesized as Raf kinase inhibitors. Scaffolds were assessed for in vitro BrafV600E inhibition, and overall kinase selectivity. Pharmacokinetic parameters for one of the scaffolds were also determined.

NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase

New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.